AKT1 and familial pancreatic carcinoma: In fact, it was also reported that combined targeting of the epidermal growth factor receptor effector AKT and the glutathione antioxidant pathway mimicked Nrf2 ablation to potently inhibit pancreatic cancer, representing a promising synthetic lethal strategy for treating pancreatic cancer (Chio et al., 2016).